Alzinova AB

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div yield, %

—

Shrs. gr., 5y

41.63%

Rev. gr., 5y

-66.21%

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.

URL

https://www.alzinova.com/

IPO date

Nov 25, 2015

Employees

Domiciled in

Incorporated in

Valuation

No data to show